Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
Wang X, Deng Y, Zhang Y, Liu T, Yuan X, Yang J, Zhang T, Zang A, Liu Y, Huang L, Ye F, Zong H, Ba Y, Klauck I, Vedovato J, Groc M, Guo A, Shen L. Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study. Journal Of Clinical Oncology 2024, 42: lba3559-lba3559. DOI: 10.1200/jco.2024.42.17_suppl.lba3559.Peer-Reviewed Original ResearchMutant metastatic colorectal cancerTreatment-emergent adverse eventsMetastatic colorectal cancerBRAF V600E mutationChinese patientsControl armMetastatic treatmentV600E mutationGrade 3BRAF V600E-mutated mCRCFrequent treatment-emergent adverse eventsColorectal cancerTreatment-related grade 3CRC studyBaseline ECOG performance statusCombination of encorafenibSafety lead-inEmergent adverse eventsData cut-offMedian patient ageECOG performance statusPrimary cancer siteConfirmed ORRMedian OSMedian PFS